echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > National Health and Health Commission issues major national science and technology projects in the field of medicine and health

    National Health and Health Commission issues major national science and technology projects in the field of medicine and health

    • Last Update: 2019-07-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The national health and Health Commission released the progress and trends of major national science and technology projects in the field of medicine and health, including new drug development projects and infectious diseases projects, as follows: new drug development projects Under the support of major new drug creation science and technology projects (hereinafter referred to as "new drug projects"), PD-1 monoclonal antibody (carrelizumab, trade name: Alito) independently developed by Hengrui pharmaceutical, a pharmaceutical enterprise in China, was approved by the National Drug Administration (nmpa) on May 28, 2019 The indication of carrizumab was recurrent / refractory classic Hodgkin's lymphoma (CHL) CHL is a B-cell lymphoma Although the first-line treatment such as chemotherapy and radiotherapy has good clinical benefits, 15% - 20% of the patients recur after the first-line treatment These patients urgently need new treatment drugs The results of clinical trials show that carrizumab has obvious clinical effect on patients with recurrent / refractory Chl Its listing brings more treatment options to patients with Chl It is a major breakthrough in independent research and development of innovative drugs in the field of immunotherapy in China, and it effectively accelerates the transformation process of China's pharmaceutical research and development from imitation to creation and the pharmaceutical industry from a large country to a powerful country With the support of the new drug project, on May 31, 2019, benwemod cream (trade name: xinbike), a global first in class new drug developed by Tianji pharmaceutical and a class 1 new drug with complete independent intellectual property rights, was approved by nmpa for listing through the priority review and approval process, and was used for local treatment of mild to moderate stable psoriasis vulgaris in adults Benwimod is a small non hormonal chemical It can inhibit T cell tyrosine protein kinase, interfere / block the release of cytokines and inflammatory mediators The results of phase III large sample clinical research in China show that benwemod cream is safe and effective in the treatment of psoriasis, and it can be used for local skin effects Therefore, there is no systemic adverse reaction related to treatment, and it has significant advantages such as quick onset, long-lasting effect, low recurrence rate after drug withdrawal and long remission period The marketing of benwemod cream will provide a new drug treatment for adults with mild to moderate stable psoriasis vulgaris The infectious diseases project is a cooperative team composed of China Center for Disease Control and prevention, Peking University and international scholars It was recently published in nature According to the research results of communications, CD8 + T cells extracted and expanded when using HIV vaccine to induce the peak of cellular immune response can reduce or completely inhibit the virus rebound after drug withdrawal, and animals with significant immune effect can inhibit the virus load for more than two months under the detection level Further studies showed that the effect of immunosuppression was dose-dependent on the CTL response of anti HIV-1 env epitopes in the reinfusion cells The multi-functional response, killing ability, activation level and differentiation degree of Env specific CD8 + T cells in the fully controlled animals were significantly higher than those in the partially controlled animals Knocking out the CD8 + T cells with good immunosuppressive effect can make the viral load quickly jump to the level before immunotherapy, which proves that CD8 + T cells mediate the control of the virus This study is the first to prove that the vaccine induced CTL adoptive immunotherapy can control the virus rebound after antiviral treatment is stopped in rhesus monkey model, which provides a new strategy for the functional cure of AIDS Zhu Shishu, et al From the fifth medical center of PLA General Hospital (the former PLA No 302 Hospital) carried out a real world cohort study, aiming at infants under 1 year old, with sustained ALT rise and high HBV viral load, which confirmed the effectiveness and safety of antiviral therapy for infant hepatitis B The results of the study were published online recently in Journal of Hepatology Most of the children infected with HBV in infancy have no symptoms and normal ALT, but a small number of children will have hepatitis attack and transaminase rise in clinical practice; on the other hand, the most serious problem for HBV infection in infancy is that most of them will become chronic However, there is still a lack of current research data on whether antiviral therapy should be used in infantile hepatitis B (ALT elevation) Accordingly, there is also a lack of expert consensus or guidance The results of this study preliminarily answered this question The results showed that early antiviral treatment for infant hepatitis B patients could achieve rapid decrease and significant clearance of HBsAg Further experiments will be carried out on a larger scale to verify the results of this study.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.